Comparative Proteomic Profiling of Mycobacterium tuberculosis and the Thai Vaccine Strain Mycobacterium bovis Bacille Calmette-Guerin Tokyo172: Diverse Biomarker Candidates for Species Differentiation
- PMID: 30581260
- PMCID: PMC6276322
- DOI: 10.4103/jgid.jgid_149_17
Comparative Proteomic Profiling of Mycobacterium tuberculosis and the Thai Vaccine Strain Mycobacterium bovis Bacille Calmette-Guerin Tokyo172: Diverse Biomarker Candidates for Species Differentiation
Abstract
Background: Bacille Calmette-Guerin (BCG)-related complications can occur in vaccinated children. Comparison of the composition of cellular proteins of virulent Mycobacterium tuberculosis (MTB) H37Rv with of attenuated Mycobacterium bovis BCG Tokyo172 vaccine strain used in Thailand and identify protein candidates of value for differentiation between the two mycobacterial species may facilitate the diagnosis of etiologic agent of mycobacterial disease in vaccinated children, as most cases have been believed to have originated from BCG vaccine.
Materials and methods: The two-dimensional electrophoresis (2DE) proteomic profiles of cellular proteins from the Thai vaccine strain M. bovis BCG Tokyo172 and MTB were compared and the matched spots in 2DE gels were submitted to mass spectrometry analysis.
Results: There were a number of similar protein contents with different intensity or position between MTB and M. bovis BCG Tokyo172. A higher expression of some immunogenic proteins was shown in BGG Tokyo172 when compared to MTB, while some were shown the opposite pattern.
Conclusions: Proteomic approach reveals key proteins participating in different species of Mycobacteria, and may be useful for discrimination between MTB and the BCG Tokyo172 infection.
Keywords: Bacille Calmette–Guerin-related complications; Mycobacterium bovis BCG Tokyo172; Mycobacterium tuberculosis; proteomics.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Comparative transcriptomics reveals common and strain-specific responses of human macrophages to infection with Mycobacterium tuberculosis and Mycobacterium bovis BCG.Microb Pathog. 2024 Apr;189:106593. doi: 10.1016/j.micpath.2024.106593. Epub 2024 Feb 20. Microb Pathog. 2024. PMID: 38387847
-
Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur.BMC Microbiol. 2011 Apr 20;11:80. doi: 10.1186/1471-2180-11-80. BMC Microbiol. 2011. PMID: 21507239 Free PMC article.
-
Molecular detection of pre-ribosomal RNAs of Mycobacterium bovis bacille Calmette-Guérin and Mycobacterium tuberculosis to enhance pre-clinical tuberculosis drug and vaccine development.Diagn Microbiol Infect Dis. 2024 Jan;108(1):116106. doi: 10.1016/j.diagmicrobio.2023.116106. Epub 2023 Oct 16. Diagn Microbiol Infect Dis. 2024. PMID: 37931386 Free PMC article.
-
Next-Generation Vaccines Based on Bacille Calmette-Guérin.Front Immunol. 2018 Feb 5;9:121. doi: 10.3389/fimmu.2018.00121. eCollection 2018. Front Immunol. 2018. PMID: 29459859 Free PMC article. Review.
-
Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?Vaccine. 2015 Sep 22;33(39):5035-41. doi: 10.1016/j.vaccine.2015.08.033. Epub 2015 Aug 28. Vaccine. 2015. PMID: 26319069 Free PMC article. Review.
Cited by
-
The role of antibiotic-derived mycobacterial vesicles in tuberculosis pathogenesis.Sci Rep. 2024 Nov 15;14(1):28198. doi: 10.1038/s41598-024-79215-3. Sci Rep. 2024. PMID: 39548211 Free PMC article.
-
New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis.Front Chem. 2020 Jul 31;8:600. doi: 10.3389/fchem.2020.00600. eCollection 2020. Front Chem. 2020. PMID: 32850635 Free PMC article. Review.
-
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.Front Immunol. 2024 May 10;15:1387454. doi: 10.3389/fimmu.2024.1387454. eCollection 2024. Front Immunol. 2024. PMID: 38799468 Free PMC article.
References
-
- World Health Organization. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization; 2014.
-
- Brosch R, Behr MA. In: Tuberculosis and the tubercle bacillus. Cole ST, Eisenach KD, McMurray DN, Jacobs WR Jr, editors. Washington DC: American Society of Microbiology; 2006. pp. 155–64.
-
- World Health Organization. Supplementary Information on Vaccine Safety by World Health Organization: Part 2: Background and Rates of Adverse Events Following Immunization. Geneva, Switzerland: World Health Organization; 2000.